Similar articles

• Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.

  Stewart J, George A, Banerjee S. Stewart J, et al. Expert Rev Anticancer Ther. 2018 Oct;18(10):947-958. doi: 10.1080/14737140.2018.1510323. Epub 2018 Aug 24. Expert Rev Anticancer Ther. 2018. PMID: 30092674 Review.
• Olaparib, a new hope for ovarian cancer.

  Samoon Z, Jabbar AA. Samoon Z, et al. Indian J Cancer. 2020 Jul-Sep;57(3):346-347. doi: 10.4103/ijc.IJC_1_19. Indian J Cancer. 2020. PMID: 32675438 No abstract available.
• Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

  Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Rafii S, et al. Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005. Oncotarget. 2017. PMID: 28454085 Free PMC article.
• ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2^-/- Ovarian Cancer Cells.

  Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE. Liu L, et al. Mol Cancer Ther. 2020 Jan;19(1):199-210. doi: 10.1158/1535-7163.MCT-19-0242. Epub 2019 Sep 18. Mol Cancer Ther. 2020. PMID: 31534014 Free PMC article.
• New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.

  Liu FW, Tewari KS. Liu FW, et al. Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9. Curr Treat Options Oncol. 2016. PMID: 26931795 Free PMC article. Review.